ProQR to Present at Upcoming SVB Leerink Conference

Rhea-AI Summary

ProQR Therapeutics N.V. (Nasdaq: PRQR) announced its participation in the virtual SVB Leerink 11th Annual Global Healthcare Conference on February 17, 2022. The presentation will be available via live webcast from 1:40 – 2:05 PM EST. ProQR focuses on transformative RNA therapies targeting genetic eye diseases like Leber congenital amaurosis 10 and Usher syndrome. Details for the webcast can be accessed through the company’s website, with archived content available for 30 days post-event.

LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 07, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced that Company management will present at the upcoming virtual SVB Leerink 11^th Annual Global Healthcare Conference. The presentation will be webcast live on February 17, 2022 from 1:40 – 2:05pm EST.

Presentation and webcast details will be accessible from the “Investors & Media” section of ProQR’s website (www.proqr.com) under “Events”. Archived webcasts will be available for approximately 30 days following the presentation date.

About ProQR

ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA therapies for the treatment of severe genetic rare diseases such as Leber congenital amaurosis 10, Usher syndrome and retinitis pigmentosa. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind.

Learn more about ProQR at www.proqr.com.

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Such forward-looking statements include, but are not limited to, statements regarding our participation in this conference. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors in our filings made with the Securities and Exchange Commission, including certain sections of our annual report filed on Form 20-F. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.

ProQR Therapeutics N.V.

Investor Contact:
Sarah Kiely
ProQR Therapeutics N.V.
T: +1 617 599 6228
skiely@proqr.com
or
Hans Vitzthum
LifeSci Advisors
T: +1 617 430 7578
hans@lifesciadvisors.com

Media Contact:
Robert Stanislaro
FTI Consulting
T: +1 212 850 5657
robert.stanislaro@fticonsulting.com

FAQ

When is ProQR's presentation at the SVB Leerink 11th Annual Global Healthcare Conference?

ProQR's presentation is scheduled for February 17, 2022, from 1:40 to 2:05 PM EST.

Where can I watch ProQR's presentation live?

The presentation will be webcast live on ProQR's website under the 'Investors & Media' section.

What does ProQR Therapeutics focus on?

ProQR specializes in RNA therapies for severe genetic eye diseases, including Leber congenital amaurosis 10 and Usher syndrome.

How long will the ProQR presentation be available for viewing after the event?

The archived webcast will be available for approximately 30 days following the presentation.

What is ProQR's stock symbol?

ProQR's stock symbol is PRQR, listed on Nasdaq.